{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T05:24:37Z","timestamp":1786944277074,"version":"build-2736575974"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To investigate the correlation of CD56 expression with clinical prognosis and adverse prognostic indicators in patients with newly diagnosed multiple myeloma (NDMM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We conducted a retrospective cohort study of 153 NDMM patients treated at Jiaozuo People\u2019s Hospital Affiliated to Henan Medical University between May 2014 and August 2024. Patients were stratified into the bortezomib cohort and the non-bortezomib cohort based on their treatment regimens, and were further divided into CD56\n                      <jats:sup>+<\/jats:sup>\n                      group and CD56\n                      <jats:sup>\u2212<\/jats:sup>\n                      group according to CD56 expression status determined by flow cytometry. Prognosis and clinicopathological characteristics were compared between groups stratified by CD56 expression and treatment regimen.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      No statistically significant differences in median progression-free survival (PFS) or overall survival (OS) were observed between the CD56\n                      <jats:sup>+<\/jats:sup>\n                      and CD56\n                      <jats:sup>\u2212<\/jats:sup>\n                      groups. Median PFS and OS were significantly longer in the bortezomib-based cohort than in the non-bortezomib cohort, whereas no significant differences were found among patients treated with VCD, VTD, or VRD regimens. Within the bortezomib-based cohort, no significant difference in median PFS or OS was observed between CD56\n                      <jats:sup>+<\/jats:sup>\n                      and CD56\n                      <jats:sup>\u2212<\/jats:sup>\n                      patients. In contrast, within the non-bortezomib cohort, CD56\n                      <jats:sup>\u2212<\/jats:sup>\n                      patients had significantly shorter median PFS and OS than CD56\n                      <jats:sup>+<\/jats:sup>\n                      patients. Among CD56\n                      <jats:sup>\u2212<\/jats:sup>\n                      patients, no significant differences in median PFS or OS were observed across the VCD, VTD, and VRD regimens. CD56 deficiency was associated with multiple adverse prognostic indicators, including thrombocytopenia, elevated \u03b2\n                      <jats:sub>2<\/jats:sub>\n                      -microglobulin (\u03b2\n                      <jats:sub>2<\/jats:sub>\n                      -MG), bone marrow fibrosis, advanced International Staging System (ISS) stage, complex karyotype, and cytogenetic aberrations.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Bortezomib-based therapy may attenuate the adverse prognostic impact associated with CD56 deficiency. CD56 expression has prognostic significance in NDMM and is closely correlated with multiple adverse clinicopathological indicators; however, it does not serve as an independent prognostic factor for NDMM patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1855388","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T04:34:30Z","timestamp":1786941270000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic significance of CD56 expression in newly diagnosed multiple myeloma and its correlation with clinicopathological features"],"prefix":"10.3389","volume":"16","author":[{"given":"Pei","family":"Pei","sequence":"first","affiliation":[{"name":"Laboratory of Hematological Diseases, Jiaozuo People\u2019s Hospital Affiliated to Henan Medical University","place":["Jiaozuo, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"Lv","sequence":"additional","affiliation":[{"name":"Laboratory of Hematological Diseases, Jiaozuo People\u2019s Hospital Affiliated to Henan Medical University","place":["Jiaozuo, Henan, China"]},{"name":"Department of Hematology, Jiaozuo People\u2019s Hospital Affiliated to Henan Medical University","place":["Jiaozuo, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boyuan","family":"Zheng","sequence":"additional","affiliation":[{"name":"School of Clinical Medicine, Henan University","place":["Kaifeng, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangqi","family":"Lv","sequence":"additional","affiliation":[{"name":"Laboratory of Hematological Diseases, Jiaozuo People\u2019s Hospital Affiliated to Henan Medical University","place":["Jiaozuo, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjun","family":"Bai","sequence":"additional","affiliation":[{"name":"Department of Hematology, Jiaozuo People\u2019s Hospital Affiliated to Henan Medical University","place":["Jiaozuo, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Li","sequence":"additional","affiliation":[{"name":"Laboratory of Hematological Diseases, Jiaozuo People\u2019s Hospital Affiliated to Henan Medical University","place":["Jiaozuo, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinglin","family":"Song","sequence":"additional","affiliation":[{"name":"Laboratory of Hematological Diseases, Jiaozuo People\u2019s Hospital Affiliated to Henan Medical University","place":["Jiaozuo, Henan, China"]},{"name":"Department of Hematology, Jiaozuo People\u2019s Hospital Affiliated to Henan Medical University","place":["Jiaozuo, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhizhong","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Jiaozuo People\u2019s Hospital Affiliated to Henan Medical University","place":["Jiaozuo, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Xu","sequence":"additional","affiliation":[{"name":"School of Basic Medical Sciences & School of Public Health, Faculty of Medicine, Yangzhou University","place":["Yangzhou, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Laboratory of Hematological Diseases, Jiaozuo People\u2019s Hospital Affiliated to Henan Medical University","place":["Jiaozuo, Henan, China"]},{"name":"Department of Clinical Pharmacy, Jiaozuo People\u2019s Hospital Affiliated to Henan Medical University","place":["Jiaozuo, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41572-024-00529-7","article-title":"Multiple myeloma","volume":"10","author":"Malard","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2024.101168","article-title":"Chromosomal defects in multiple myeloma","volume":"64","author":"Clarke","year":"2024","journal-title":"Blood Rev"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.5045\/br.2020.S007","article-title":"Frontline therapy for newly diagnosed patients with multiple myeloma","volume":"55","author":"Jung","year":"2020","journal-title":"Blood Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13184666","article-title":"Rapid progress in the use of immunomodulatory drugs and cereblon E3 ligase modulators in the treatment of multiple myeloma","volume":"13","author":"Charli\u0144ski","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B5","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s40164-023-00434-x","article-title":"Lysin (K)-specific demethylase 1 inhibition enhances proteasome inhibitor response and overcomes drug resistance in multiple myeloma","volume":"12","author":"Bandini","year":"2023","journal-title":"Exp Hematol Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13061285","article-title":"Multiple myeloma: heterogeneous in every way","volume":"13","author":"Schavgoulidze","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2019.100643","article-title":"The evolving role of translocation t(11;14) in the biology, prognosis, and management of multiple myeloma","volume":"41","author":"Paner","year":"2020","journal-title":"Blood Rev"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00593-y","article-title":"Single-cell profiling of tumour evolution in multiple myeloma - opportunities for precision medicine","volume":"19","author":"Dutta","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.22024","article-title":"Malignant plasmacytes in bone marrow detected by flow cytometry as a predictor for the risk stratification system of multiple myeloma","volume":"102","author":"Tian","year":"2022","journal-title":"Cytom Part B-Clin Cy"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01206-4","article-title":"A prognostic survival model based on metabolism-related gene expression in plasma cell myeloma","volume":"35","author":"Huang","year":"2021","journal-title":"Leukemia"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6103","article-title":"Plasma cell myeloma with RAS\/BRAF mutations is frequently associated with a complex karyotype, advanced stage disease, and poorer prognosis","volume":"12","author":"Li","year":"2023","journal-title":"Cancer Med"},{"key":"B12","article-title":"Prognostic value of CD56 expression in newly diagnosed multiple myeloma patients and its related factors","volume":"31","author":"Wang","year":"2023","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2021.153567","article-title":"CD56 expression in multiple myeloma: Correlation with poor prognostic markers but no effect on outcome","volume":"225","author":"Koumpis","year":"2021","journal-title":"Pathol Res Pract"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2021.2019365","article-title":"Prognostic significance of CD56 expression in patients with multiple myeloma: a meta-analysis","volume":"27","author":"Zhang","year":"2022","journal-title":"Hematology"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11216524","article-title":"Dual negativity of CD56 and CD117 links to unfavorable cytogenetic abnormalities and predicts poor prognosis in multiple myeloma","volume":"11","author":"Zheng","year":"2022","journal-title":"J Clin Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000030988","article-title":"Prognostic significance of CD56 antigen in newly diagnosed multiple myeloma: A real-world retrospective study","volume":"101","author":"Li","year":"2022","journal-title":"Medicine"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1097\/cad.0000000000001041","article-title":"The paradoxical pharmacological mechanisms of lenalidomide and bortezomib in the treatment of multiple myeloma","volume":"32","author":"Wang","year":"2021","journal-title":"Anti-Cancer Drug"},{"key":"B18","article-title":"Guidelines for the diagnosis and management of multiple myeloma in China (2024 revision)","volume":"63","year":"2024","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25791","article-title":"Multiple myeloma: 2020 update on diagnosis, risk-stratification and management","volume":"95","author":"Rajkumar","year":"2020","journal-title":"Am J Hematol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-023-05588-6","article-title":"1q21+ is associated with poor prognosis in newly diagnosed multiple myeloma patients with extramedullary disease: a retrospective study","volume":"103","author":"Gao","year":"2024","journal-title":"Ann Hematol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1186\/s12885-024-13309-z","article-title":"The impact of high-risk cytogenetic abnormalities in extramedullary multiple myeloma in the era of novel agents: insights from a multicenter study","volume":"24","author":"Liang","year":"2024","journal-title":"BMC Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2025.287545","article-title":"Comprehensive evaluation of disease characteristics and outcomes of patients with extramedullary multiple myeloma in the modern era","volume":"110","author":"Broughton","year":"2025","journal-title":"Haematologica"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102284","article-title":"Roadmap to cure multiple myeloma","volume":"100","author":"Rodriguez-Otero","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"New Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13045-024-01530-z","article-title":"Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial","volume":"17","author":"Xu","year":"2024","journal-title":"J Hematol Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02515","article-title":"Long-term follow-up results of lenalidomide, bortezomib, and dexamethasone induction therapy and risk-adapted maintenance approach in newly diagnosed multiple myeloma","volume":"38","author":"Joseph","year":"2020","journal-title":"J Clin Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41408-020-0298-1","article-title":"Bortezomib-based consolidation or maintenance therapy for multiple myeloma: a meta-analysis","volume":"10","author":"Zhang","year":"2020","journal-title":"Blood Cancer J"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-01021-3","article-title":"Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse","volume":"35","author":"Dimopoulos","year":"2021","journal-title":"Leukemia"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13280","article-title":"Upfront bortezomib, lenalidomide, and dexamethasone compared to bortezomib, cyclophosphamide, and dexamethasone in multiple myeloma","volume":"103","author":"Uttervall","year":"2019","journal-title":"Eur J Haematol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2729","article-title":"Real world outcomes with bortezomib thalidomide dexamethasone and cyclophosphamide bortezomib dexamethasone induction treatment for transplant eligible multiple myeloma patients in a Latin American country. A retrospective cohort study from Grupo Argentino de mieloma m\u00faltiple","volume":"38","author":"Sch\u00fctz","year":"2020","journal-title":"Hematol Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/jca.21864","article-title":"Is absence of CD56 a predictive factor for peripheral blood stem cell mobilization failure in patients with multiple myeloma","volume":"36","author":"G\u00f6\u00e7er","year":"2021","journal-title":"J Clin Apheresis"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03513.x","article-title":"Clinicopathological and prognostic characteristics of CD56-negative multiple myeloma","volume":"117","author":"Sahara","year":"2002","journal-title":"Brit J Haematol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-21-0828","article-title":"Redefining CD56 as a biomarker and therapeutic target in multiple myeloma","volume":"20","author":"Cottini","year":"2022","journal-title":"Mol Cancer Res"},{"key":"B35","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.leukres.2015.11.003","article-title":"Absence of both CD56 and CD117 expression on Malignant plasma cells is related with a poor prognosis in patients with newly diagnosed multiple myeloma","volume":"40","author":"Pan","year":"2016","journal-title":"Leukemia Res"},{"key":"B36","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s12032-020-01423-4","article-title":"The clinical significance of CD49e and CD56 for multiple myeloma in the novel agents era","volume":"37","author":"Okura","year":"2020","journal-title":"Med Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2017.5920","article-title":"Clinical effect of immunophenotyping on the prognosis of multiple myeloma patients treated with bortezomib","volume":"13","author":"Iriyama","year":"2017","journal-title":"Oncol Lett"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.4274\/tjh.2016.0394","article-title":"The assessment of CD56 and CD117 expressions at the time of the diagnosis in multiple myeloma patients","volume":"34","author":"Ceran","year":"2017","journal-title":"Turk J Hematol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1159\/000489483","article-title":"CD56 expression is an important prognostic factor in multiple myeloma even with bortezomib induction","volume":"139","author":"Skerget","year":"2018","journal-title":"Acta Haematol-Basel"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0181447","article-title":"Prognostic value of circulating plasma cells in patients with multiple myeloma: A meta-analysis","volume":"12","author":"Li","year":"2017","journal-title":"PLoS One"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-06-510453","article-title":"Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile","volume":"122","author":"Paiva","year":"2013","journal-title":"Blood"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1111\/ijlh.13387","article-title":"Adhesion molecule immunophenotype of bone marrow multiple myeloma plasma cells impacts the presence of Malignant circulating plasma cells in peripheral blood","volume":"43","author":"Klimien\u0117","year":"2021","journal-title":"Int J Lab Hematol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.21801","article-title":"Antigen expression patterns of plasma cell myeloma: an association of cytogenetic abnormality and International Staging System (ISS) for myeloma","volume":"29","author":"Shin","year":"2015","journal-title":"J Clin Lab Anal"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3960\/jslrt.55.137","article-title":"Cytogenetic study and analysis of protein expression in plasma cell myeloma with t(11;14)(q13;q32): absence of BCL6 and SOX11, and infrequent expression of CD20 and PAX5","volume":"55","author":"Yokoi","year":"2015","journal-title":"J Clin Exp Hematop"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705857","article-title":"Lack of CD56 expression on myeloma cells is not a marker for poor prognosis in patients treated by high-dose chemotherapy and is associated with translocation t(11;14)","volume":"40","author":"Hundemer","year":"2007","journal-title":"Bone Marrow Transpl"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.4","article-title":"Genetic aberrations and survival in plasma cell leukemia","volume":"22","author":"Tiedemann","year":"2008","journal-title":"Leukemia"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2009.107","article-title":"1p21 deletions are strongly associated with 1q21 gains and are an independent adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma","volume":"45","author":"Chang","year":"2010","journal-title":"Bone Marrow Transpl"},{"key":"B48","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1080\/15513815.2020.1765917","article-title":"Expression of CD56 is not limited to biliary atresia and correlates with the degree of fibrosis in pediatric cholestatic diseases","volume":"41","author":"Ayyanar","year":"2022","journal-title":"Fetal Pediatr Pathol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1309\/AJCPNC99DHXIOOTD","article-title":"Aberrant myeloid maturation identified by flow cytometry in primary myelofibrosis","volume":"133","author":"Feng","year":"2010","journal-title":"Am J Clin Pathol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1855388\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T04:34:33Z","timestamp":1786941273000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1855388\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,17]]},"references-count":49,"alternative-id":["10.3389\/fonc.2026.1855388"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1855388","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,17]]},"article-number":"1855388"}}